Neurology

Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners

For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC / ACCESSWIRE / August…

1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded…

1 year ago

Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

Key scientific achievements drive the expansion of the pipeline of molecular glue degradersPerformance-based and programme-based payments of in total US$…

1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallySARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE)…

1 year ago

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress…

1 year ago

Natus introduces autoSCORE, an innovative AI solution capable of a new era of expert-level clinical EEG interpretation

MIDDLETON, Wis., Aug. 7, 2024 /PRNewswire/ -- Natus Medical Incorporated has announced the launch of autoSCORE, the first-of-its-kind artificial intelligence…

1 year ago

Evotec SE Reports First Half-year 2024 Results on 14 August 2024

HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will…

1 year ago

Applied Therapeutics Reports Second Quarter 2024 Financial Results

NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action…

1 year ago

Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

CNM-Au8 treated participants in the HEALEY ALS Platform Trial with substantial neurofilament light (NfL) declines (CNM-Au8 NfL Responders) demonstrated significant…

1 year ago